Drug-induced red cell dyscrasias

Area of Science:

• Hematology
• Toxicology
• Pharmacology

Background:

• Drug-induced blood dyscrasias are a significant clinical concern.
• Red blood cell abnormalities are the most frequent type of drug-induced hematologic toxicity.
• Advances in understanding pathogenesis have improved diagnosis and management.

Purpose of the Study:

• To review the pathogenetic mechanisms of drug-induced red blood cell dyscrasias.
• To highlight the immunological and metabolic pathways involved in drug-induced hemolysis.
• To discuss drugs affecting erythroid precursors and heme synthesis.

Main Methods:

• Literature review focusing on pathogenetic mechanisms.
• Analysis of clinical and laboratory manifestations of drug-induced hemolysis.
• Summary of drug effects on red blood cell metabolism and erythropoiesis.

Main Results:

• Drug-induced red cell destruction occurs via immune mechanisms or metabolic disruption.
• Oxidative hemolysis is common, particularly in individuals with glucose-6-phosphate dehydrogenase deficiency.
• Drugs can impair erythroid growth, DNA synthesis (megaloblastic), or heme synthesis (sideroblastic).

Conclusions:

• A comprehensive understanding of drug-induced hematologic toxicity is crucial.
• Differential diagnosis requires considering immune, metabolic, and precursor-related mechanisms.
• An updated list of implicated drugs aids in clinical practice and further research.